Skip to content
Search

Latest Stories

New repeat prescribing toolkit to improve patient care, reduce medicine waste

New repeat prescribing toolkit to improve patient care, reduce medicine waste

By streamlining repeat prescribing systems, the RPS/RCGP toolkit aims to reduce the impact of overprescribing and problematic polypharmacy

The Royal Pharmaceutical Society (RPS) and the Royal College of GPs (RCGP) have launched a new toolkit to enhance the consistency, safety, and efficiency of repeat prescribing systems in general practices across England.

Commissioned by NHS England, this toolkit is the first national good practice guidance for repeat prescribing in two decades and aims to address issues highlighted by the 2021 National Overprescribing Review.


The review recognised the impact that poorly operated repeat prescribing can have on overprescribing and problematic polypharmacy.

Over 1 billion prescriptions are dispensed annually in England, 77% of which are repeat prescriptions, which account for nearly 80% of NHS primary care medicine costs.

The sheer volume and workload of repeat prescriptions underscore the need for streamlined and improved processes.

The RPS/RCGP Repeat Prescribing Toolkit allows GP practice teams and primary care networks, working in collaboration with community pharmacies and patients, to create a “collaborative, safe and efficient” repeat prescribing process.

This approach aims to enhance patient care by addressing inconsistencies and potential oversupply, whilst reducing unnecessary medicines waste and saving NHS resources.

Clare Howard, RPS Fellow and Clinical Lead author, noted that this toolkit marks a significant step forward in ensuring the safety and efficiency of repeat prescribing systems, ultimately benefiting patients and the NHS as a whole.

“By working together, the RPS and RCGP have developed practical guidance and useful resources which will enable GP practices and Primary Care Networks to self-assess their current arrangements and make meaningful improvements in their repeat prescribing processes,” she explained.

The toolkit also includes practical guidance on improving communication with patients about repeat prescribing, supported by good practice case studies, flow charts, action plan templates, and useful resources.

Dr Michael Mulholland, Honorary Secretary of the RCGP, emphasised that safe and appropriate prescribing is a key skill for GPs, and they take it “very seriously”

“Repeat prescribing makes up a large part of the general practice workload and we need to make sure we are always streamlining and improving the process,” he said.

To complement the toolkit, a new NHS dashboard has been developed to highlight potential oversupply of medicines in various prescribing areas. The dashboard will support improvement initiatives, particularly by identifying inconsistencies in repeat prescribing processes, to help minimise avoidable waste and the risk of patient harm.

Graham Prestwich, patient representative and Board Member at Healthwatch Leeds, stated that the toolkit and associated resources will help make communicating with patients about their repeat medicines “simpler and more effective."

Professor Tony Avery, National Clinical Director for Prescribing at NHS England, emphasised the importance of the tool, stating: “With over one billion prescriptions dispensed annually in England, over three quarters of which are repeat prescriptions, it is essential that repeat prescribing systems in general practices are safe for patients and efficient for all involved.”

The toolkit is now available for use by general practices, Primary Care Networks, Integrated Care Boards, and community pharmacies across England.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less